Mol Ther Oncolytics

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.

Wenthe J, Naseri S, Hellström AC, ..., Eriksson E, Loskog A

Mol Ther Oncolytics 24 (-) 429-442 [2022-03-17; online 2022-01-10]

Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus.

Ma J, Jin C, Čančer M, ..., Ramachandran M, Yu D

Mol Ther Oncolytics 21 (-) 356-366 [2021-06-25; online 2021-05-05]

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.

Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A

Mol Ther Oncolytics 20 (-) 508-518 [2021-03-26; online 2021-02-17]

Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity.

Sarén T, Ramachandran M, Martikainen M, Yu D

Mol Ther Oncolytics 7 (-) 67-75 [2017-12-15; online 2017-10-05]

Affiliated researcher